Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis

Translational Research

Volumn 159, Issue 6, 2012, Pages 477-486

  Salamone, Federico ^a,b,c,d   Galvano, Fabio ^a,b,c,d   Cappello, Francesco ^a,b,c,d   Mangiameli, Andrea ^a,b,c,d   Barbagallo, Ignazio ^a,b,c,d   Li Volti, Giovanni ^a,b,c,d  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Istituto EuroMediterraneo di Scienza e Tecnologia   (Italy)

^d San Donato Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ACYL COENZYME A DESATURASE; ACYL COENZYME A OXIDASE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FATTY ACID BINDING PROTEIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LIPID; NITRIC OXIDE SYNTHASE; PROTEIN P50; REACTIVE OXYGEN METABOLITE; SILIBININ; SYNAPTOTAGMIN I; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HOMEOSTASIS; INSULIN BLOOD LEVEL; LIPID HOMEOSTASIS; LIPID PEROXIDATION; LIPOTOXICITY; LIVER HISTOLOGY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

EID: 84861603829     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2011.12.003     Document Type: Article

References (46)

1. G. Musso, R. Gambino, M. Cassader, and G. Pagano Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 43 2011 617 649
2. E.K. Speliotes, J.M. Massaro, and U. Hoffmann Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study Hepatology 51 2010 1979 1987
3. F. Salamone, F. Galvano, and G. Li Volti Treating fatty liver for the prevention of cardiovascular diseases Hepatology 52 2010 1174 1175
4. K.M. Korenblat, E. Fabbrini, B.S. Mohammed, and S. Klein Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects Gastroenterology 134 2008 1369 1375
5. E.M. Brunt Histopathology of non-alcoholic fatty liver disease Clin Liver Dis 13 2009 533 544
6. M. Trauner, M. Arrese, and M. Wagner Fatty liver and lipotoxicity Biochim Biophys Acta 1801 2010 299 310
7. S.K. Mantena, A.L. King, K.K. Andringa, H.B. Eccleston, and S.M. Bailey Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases Free Radic Biol Med 44 2008 1259 1272
8. F. Marra Nuclear factor-kappaB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy Gut 57 2008 570 572
9. G. Musso, R. Gambino, M. Cassader, and G. Pagano A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease Hepatology 52 2010 79 104
10. I.A. Leclercq, G.C. Farrell, C. Sempoux, P.A. Dela, and Y. Horsmans Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice J Hepatol 41 2004 926 934
11. L. Mira, M. Silva, and C.F. Manso Scavenging of reactive oxygen species by silibinin dihemisuccinate Biochem Pharmacol 48 1994 753 759
12. C. Dehmlow, J. Erhard, and H. de Groot Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin Hepatology 23 1996 749 754
13. A. Pietrangelo, F. Borella, and G. Casalgrandi Antioxidant activity of silybin in vivo during long-term iron overload in rats Gastroenterology 109 1995 1941 1949
14. J. Schumann, J. Prockl, A.K. Kiemer, A.M. Vollmar, R. Bang, and G. Tiegs Silibinin protects mice from T cell-dependent liver injury J Hepatol 39 2003 333 340
15. G. Li Volti, S. Salomone, and V. Sorrenti Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice Cardiovasc Diabetol 10 2011 62
16. A. Federico, M. Trappoliere, and C. Tuccillo A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations Gut 55 2006 901 902
17. P. Andreone, M. Brisc, and M. Chiaramonte Silybin conjugated with phosphatidylcholine and vitamin E improves liver damage in patients with NAFLD: the results of a randomized multicentre double-blind vs placebo trial J Hepatol 54 Suppl 1 2011 S330 S331
18. A. Sahai, P. Malladi, and X. Pan Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin Am J Physiol Gastrointest Liver Physiol 287 2004 G1035 G1043
19. M.E. Rinella, M.S. Elias, R.R. Smolak, T. Fu, J. Borensztajn, and R.M. Green Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet J Lipid Res 49 2008 1068 1076
20. P. Kidd, and K. Head A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos) Altern Med Rev 10 2005 193 203
21. P. Ferenci, T.M. Scherzer, and H. Kerschner Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy Gastroenterology 135 2008 1561 1567
22. J.M. Bares, J. Berger, and J.E. Nelson Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C J Clin Gastroenterol 42 2008 937 944
23. T. Osumi, T. Hashimoto, and N. Ui Purification and properties of acyl-CoA oxidase from rat liver J Biochem 87 1980 1735 1746
24. G. Woldegiorgis, T. Spennetta, B.E. Corkey, J.R. Williamson, and E. Shrago Extraction of tissue long-chain acyl-CoA esters and measurement by reverse-phase high-performance liquid chromatography Anal Biochem 150 1985 8 12
25. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
26. Z.Z. Li, M. Berk, T.M. McIntyre, and A.E. Feldstein Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase J Biol Chem 284 2009 5637 5644
27. G. Rizki, L. Arnaboldi, and B. Gabrielli Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1 J Lipid Res 47 2006 2280 2290
28. M.A. Gyamfi, I. Damjanov, S. French, and Y.J. Wan The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury Biochem Pharmacol 75 2008 981 995
29. G.H. Koek, P.R. Liedorp, and A. Bast The role of oxidative stress in non-alcoholic steatohepatitis Clin Chim Acta 412 2011 1297 1305
30. L.A. Videla, R. Rodrigo, and M. Orellana Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients Clin Sci (Lond) 106 2004 261 268
31. G. Serviddio, F. Bellanti, and R. Tamborra Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury Gut 57 2008 957 965
32. I.C. Gaemers, J.M. Stallen, and C. Kunne Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease Biochim Biophys Acta 1812 2011 447 458
33. A.J. Sanyal, N. Chalasani, and K.V. Kowdley Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
34. F. Lirussi, L. Azzalini, S. Orando, R. Orlando, and F. Angelico Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis Cochrane Database Syst Rev 1 2007 CD004996
35. M. Trujillo, G. Ferrer-Sueta, and R. Radi Peroxynitrite detoxification and its biologic implications Antioxid Redox Signal 10 2008 1607 1620
36. I. Garcia-Ruiz, C. Rodriguez-Juan, and T. Diaz-Sanjuan Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice Hepatology 44 2006 581 591
37. A. Masini, D. Ceccarelli, F. Giovannini, G. Montosi, C. Garuti, and A. Pietrangelo Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin J Bioenerg Biomembr 32 2000 175 182
38. G. Serviddio, F. Bellanti, and A.M. Giudetti A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis J Pharmacol Exp Ther 332 2010 922 932
39. G. Gloire, and J. Piette Redox regulation of nuclear post-translational modifications during NF-kappaB activation Antioxid Redox Signal 11 2009 2209 2222
40. A.M. Elsharkawy, and D.A. Mann Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis Hepatology 46 2007 590 597
41. P.S. Ribeiro, H. Cortez-Pinto, and S. Sola Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients Am J Gastroenterol 99 2004 1708 1717
42. L.A. Videla, G. Tapia, and R. Rodrigo Liver NF-kappaB and AP-1 DNA binding in obese patients Obesity (Silver Spring) 17 2009 973 979
43. P.A. Dela, I. Leclercq, J. Field, J. George, B. Jones, and G. Farrell NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis Gastroenterology 129 2005 1663 1674
44. N. Beraza, Y. Malato, and B.S. Vander Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis Gut 57 2008 655 663
45. F. Aktan iNOS-mediated nitric oxide production and its regulation Life Sci 75 2004 639 653
46. J.S. Kang, Y.J. Jeon, H.M. Kim, S.H. Han, and K.H. Yang Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide- stimulated macrophages J Pharmacol Exp Ther 302 2002 138 144